Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

This randomized phase I/II trial studies the side effects, best way to give, and best dose of erlotinib and bevacizumab when given with cetuximab and how well giving erlotinib and cetuximab together with or without bevacizumab works in treating patients with metastatic or unresectable kidney, colorectal, head and neck, pancreatic, or non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab and bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib together with cetuximab and/or bevacizumab may kill more tumor cells.

本项随机I/II期临床试验（randomized phase I/II trial）旨在评估埃罗替尼（erlotinib）联合贝伐珠单抗（bevacizumab）与西妥昔单抗（cetuximab）联用时的不良反应、最佳给药方案及最佳给药剂量，并探究埃罗替尼联合西妥昔单抗联用或不联用贝伐珠单抗治疗转移性或不可切除性肾、结直肠、头颈部、胰腺及非小细胞肺癌患者的临床疗效。埃罗替尼可通过阻断肿瘤细胞生长所需的部分酶类，抑制肿瘤细胞增殖。单克隆抗体（monoclonal antibody）如西妥昔单抗、贝伐珠单抗可通过多种机制阻滞肿瘤生长：部分单克隆抗体可阻断肿瘤细胞的增殖与扩散能力，其余则可靶向识别肿瘤细胞，协助杀伤肿瘤细胞或向肿瘤细胞递送抗肿瘤物质。西妥昔单抗与贝伐珠单抗还可通过阻断肿瘤供血血管，抑制肿瘤细胞生长。埃罗替尼联合西妥昔单抗及/或贝伐珠单抗给药，可更高效地杀伤肿瘤细胞。